secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hoth Therapeutics, Inc. (HOTH)
CIK:        0001711786
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001213900-25-031763
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hoth Therapeutics reports positive Phase 2a interim data for HT-001: 50% reduction in pruritus by Day 21
--------------------------------------------------------------------------------

- Mean pruritus score dropped 50% from 1.6 to 0.8 by Day 21 in open-label portion of CLEER-001 Phase 2a trial.
- Rapid symptom relief: mean score improved to 1.0 by Day 7; some patients achieved complete resolution within 21 days.
- HT-001 was well tolerated with no treatment-related serious adverse events reported.
- Director Graig Springer resigned effective April 15, 2025; Wayne Linsley appointed as chair of nominating and governance committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711786/000121390025031763/0001213900-25-031763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711786/000121390025031763/ea0238201-8k_hoth.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-031763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer